These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 15369772

  • 21. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 22. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
    Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA.
    Clin Cancer Res; 2000 Oct 15; 6(10):4119-27. PubMed ID: 11051265
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.
    Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C.
    Exp Cell Res; 2005 Mar 10; 304(1):244-55. PubMed ID: 15707589
    [Abstract] [Full Text] [Related]

  • 24. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 25. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 26. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A, Lam A, Datta R, Srivastava RK.
    Oncogene; 2001 Apr 19; 20(17):2122-33. PubMed ID: 11360196
    [Abstract] [Full Text] [Related]

  • 27. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S.
    Anticancer Res; 2006 Apr 19; 26(1A):259-65. PubMed ID: 16475706
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
    Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS.
    Oncogene; 2002 May 09; 21(20):3139-48. PubMed ID: 12082629
    [Abstract] [Full Text] [Related]

  • 32. Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.
    Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, Belka C.
    Oncogene; 2005 Jan 06; 24(1):130-40. PubMed ID: 15531922
    [Abstract] [Full Text] [Related]

  • 33. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
    Kim EJ, Suliman A, Lam A, Srivastava RK.
    Int J Oncol; 2001 Jan 06; 18(1):187-94. PubMed ID: 11115558
    [Abstract] [Full Text] [Related]

  • 34. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis.
    Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR.
    Cancer Res; 2001 Feb 01; 61(3):1138-43. PubMed ID: 11221844
    [Abstract] [Full Text] [Related]

  • 35. Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.
    Sonnemann J, Gekeler V, Sagrauske A, Müller C, Hofmann HP, Beck JF.
    Int J Oncol; 2004 Oct 01; 25(4):1171-81. PubMed ID: 15375570
    [Abstract] [Full Text] [Related]

  • 36. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins.
    Fandy TE, Srivastava RK.
    Cancer Chemother Pharmacol; 2006 Oct 01; 58(4):471-7. PubMed ID: 16435155
    [Abstract] [Full Text] [Related]

  • 37. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB, Bhardwaj U, Takada Y.
    Vitam Horm; 2004 Oct 01; 67():453-83. PubMed ID: 15110190
    [Abstract] [Full Text] [Related]

  • 38. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells.
    Sonoda Y, Yamamoto D, Sakurai S, Hasegawa M, Aizu-Yokota E, Momoi T, Kasahara T.
    Biochem Biophys Res Commun; 2001 Feb 23; 281(2):282-8. PubMed ID: 11181042
    [Abstract] [Full Text] [Related]

  • 39. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
    Golubovskaya VM, Gross S, Kaur AS, Wilson RI, Xu LH, Yang XH, Cance WG.
    Mol Cancer Res; 2003 Aug 23; 1(10):755-64. PubMed ID: 12939401
    [Abstract] [Full Text] [Related]

  • 40. C/EBPalpha inactivation in FAK-overexpressed HL-60 cells impairs cell differentiation.
    Hashimoto K, Sonoda Y, Yamakado M, Funakoshi-Tago M, Yoshida N, Rokudai A, Aizu-Yokota E, Kasahara T.
    Cell Signal; 2006 Jul 23; 18(7):955-63. PubMed ID: 16226872
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.